The Agricultural Industry is Abuzz Over Bee Vectoring’s New Production & Research Facility

Spotlight Companies  |

Traditional pesticides used to prevent pests from destroying crops have been proven to be toxic to manufacturers and consumers. Acute pesticide poisoning is a major issue, especially in developing countries. Bee Vectoring Technologies International Inc. (BEE:CA) , a Canadian company that specializes in the delivery of required compounds to flowering plants, may now be in the position to provide a natural solution to an industry-wide problem.

Today, Bee Vectoring has officially opened the doors of its state-of-the-art production and research facility. Located in Ontario, the 7000-square-foot facility will produce, annually, up to $100 million in products used within the company’s organic pesticide systems. 

"This is a major milestone in the commercialization of a solution that has the potential to fundamentally alter how pests and diseases are controlled in the fruit and vegetables we eat,” said Michael Collinson, CEO of Bee Vectoring. “We are fortunate to have a world-class team that has developed this solution. We now have a world class facility that will enable us to scale rapidly and take advantage of significant business development opportunities we are seeing, for a disruptive solution like BVT's in the national and global food growing industry."

A Natural Solution for a Vital Industry

Bees are used to deliver natural biocontrol agents and fungal pathogens to flowering plants through BVT’s inoculum dispenser system. Although bees have the reputation of being potentially harmful pests, they are responsible for nearly one-third of the United States’ food population.

“BVT's technology is a unique solution which has major market appeal as it directly addresses the rapidly escalating needs of global organic and other growers for biological crop protection," said Claude Flueckiger, BVT Board Member & Syngenta Global Product Biology Lawn & Garden Lead.

This milestone follows the company’s recent $1.6 million private placement deal. The net proceeds of the offering were used to fund the development of BVT’s manufacturing plant, as well as general purposes, hiring and EPA approvals. The way that the world’s crops are grown and maintained is about to be forever changed. With the help of a team of internationally recognized scientists and experts now housed in this brand new facility, Bee Vectoring is harnessing the power of nature to revolutionize the agricultural industry. had the opportunity to interview Michael Collison, President and CEO of Bee vectoring. The interview can be read here. For more information about Bee Vectoring, visit

Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…